Ertugliflozin in the treatment of type 2 diabetes mellitus:a rapid health technology assessment
10.12173/j.issn.1005-0698.202405068
- VernacularTitle:艾托格列净治疗2型糖尿病的快速卫生技术评估
- Author:
Fang QIN
1
,
2
;
Kunrong WU
;
Chengyu LIU
;
Daihua LIU
Author Information
1. 柳州市人民医院药学部(广西柳州 545006)
2. 柳州市胃肠道中成药工程技术研究中心(广西柳州 545006)
- Keywords:
Ertugliflozin;
Type 2 diabetes mellitus;
Efficacy;
Safety;
Cost-effectiveness;
Rapid health technology assessment
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(7):778-789
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy,safety and cost-effectiveness of ertugliflozin in the treatment of type 2 diabetes mellitus by rapid health technology assessment to provide a basis for clinical decision-making.Methods PubMed,Embase,the Cochrane Library,CNKI,WanFang Data,VIP database and health technology assessment(HTA)related websites and databases were searched from the inception date to January 2024.Two researchers independently screened the literature,extracted the data,assessed the quality and carried out the qualitative analysis.Results A total of 27 articles were included,in which 2 HTA reports,24 systematic reviews/meta-analyses and 2 pharmacoeconomic studies.Compared with placebo,ertugliflozin could significantly lower hemoglobin Alc level,fasting plasma glucose,hospitalization for heart failure,body weight and blood pressure levels,but there were no significant difference in all-cause mortality,cardiovascular mortality and composite renal outcome.In terms of safety,there were no significant difference in the risk of urinary tract infections,fracture,amputation and symptomatic hypoglycemia between ertugliflozin and placebo or other hypoglycemic drugs.However,ertugliflozin increased the risk of ketoacidosis,genital mycotic infections and lowered of estimated glomerular filtration rate.Pharmacoeconomic studies showed that ertugliflozin had better cost-utility and cost-effectiveness in type 2 diabetes in China.Conclusion Ertugliflozin is effective and safety in treating type 2 diabetes mellitus,but it's necessary to carry out the head to head studies among efficacy,safety and economics research in China.
